Holden S A, Teicher B A, Herman T S
Dana-Farber Cancer Institute, Boston, MA.
Int J Radiat Oncol Biol Phys. 1991 May;20(5):1031-8. doi: 10.1016/0360-3016(91)90201-e.
The effect of pH on misonidazole-induced cell killing at normal and elevated temperatures and on radiosensitization by misonidazole at 37 degrees C was assessed in FSaIIC fibrosarcoma cells in vitro. At doses of 5-500 microM for 1 hr, misonidazole was 1.5- to 2-fold more toxic toward hypoxic versus euoxic cells at 37 degrees C and pH 7.40. At 42 degrees C and 43 degrees C at pH 7.40, a less than 2-fold increase in cytotoxicity was observed in both normally oxic and hypoxic cells as compared with 37 degrees C. At pH 6.45 and 37 degrees C, misonidazole was less cytotoxic toward both euoxic and hypoxic cells than at pH 7.40. Unexpectedly, exposure to misonidazole at 42 degrees C or 43 degrees C and pH 6.45 caused no significant increase in cytotoxicity over that attributable to hyperthermia alone. Similarly, the dose modifying effect of misonidazole on single radiation fractions in vitro was also reduced at pH 6.45 versus pH 7.40 (2.60 versus 2.40, p less than 0.01). In vivo, treatment of the FSaIIC tumor with misonidazole (1 g/kg) and/or local hyperthermia (43 degrees C for 30 min to the tumor-bearing limb) in conjunction with radiation (10, 20, or 30 Gy) yielded a radiation dose modifying factor for misonidazole of 1.32, for hyperthermia of 1.38, and for the combination of 2.06 (probably additive). Analysis of the cytotoxicity achieved by these treatments in Hoechst 33342 dye-selected tumor subpopulations demonstrated that, whereas radiation was more toxic toward bright (presumably euoxic) cells, misonidazole, hyperthermia, and the combination were significantly more toxic toward dim (presumably hypoxic) cells. The addition of both hyperthermia and misonidazole to radiation more than overcame the relative resistance of the dim subpopulation to 10 Gy. These results indicate that misonidazole is a reasonable drug for use with hyperthermia and radiation to increase killing of hypoxic cells, but the decrease in cytotoxicity and radiosensitizing abilities of this agent observed under acidotic conditions could reduce the effectiveness of this treatment.
在体外培养的FSaIIC纤维肉瘤细胞中,评估了pH值对正常温度和升高温度下米索硝唑诱导的细胞杀伤作用以及对37℃时米索硝唑放射增敏作用的影响。在37℃、pH 7.40条件下,当米索硝唑剂量为5 - 500 microM、作用1小时时,对缺氧细胞的毒性比对富氧细胞高1.5至2倍。在42℃和43℃、pH 7.40条件下,与37℃相比,正常有氧和缺氧细胞的细胞毒性增加不到2倍。在pH 6.45和37℃条件下,米索硝唑对富氧和缺氧细胞的细胞毒性均低于pH 7.40时。出乎意料的是,在42℃或43℃、pH 6.45条件下暴露于米索硝唑,其细胞毒性并未比单独热疗有显著增加。同样,在pH 6.45时,米索硝唑对体外单次辐射剂量的剂量修正作用也低于pH 7.40时(分别为2.60和2.40,p < 0.01)。在体内,用米索硝唑(1 g/kg)和/或局部热疗(对荷瘤肢体43℃持续30分钟)联合放疗(10、20或30 Gy)治疗FSaIIC肿瘤,米索硝唑的放射剂量修正因子为1.32,热疗为1.38,联合治疗为2.06(可能为相加作用)。通过对用Hoechst 33342染料分选的肿瘤亚群进行这些治疗后的细胞毒性分析表明,放疗对明亮(可能为富氧)细胞毒性更大,而米索硝唑、热疗及其联合治疗对暗淡(可能为缺氧)细胞毒性显著更大。热疗和米索硝唑与放疗联合使用,超过了暗淡亚群对10 Gy辐射的相对抗性。这些结果表明,米索硝唑是一种与热疗和放疗联合使用以增加缺氧细胞杀伤的合理药物,但在酸中毒条件下观察到该药物细胞毒性和放射增敏能力降低,可能会降低这种治疗的有效性。